IP Verse

Methods And Compositions For The Treatment Of Persistent Infections And Cancer By Inhibiting The Programmed Cell Death 1 (Pd-1)Pathway - EP2397155

The patent EP2397155 was granted to Dana Farber Cancer Institute on Dec 13, 2017. The application was originally filed on Jun 8, 2006 under application number EP11162667A. The patent is currently recorded with a legal status of "Revoked".

EP2397155

DANA FARBER CANCER INSTITUTE
Application Number
EP11162667A
Filing Date
Jun 8, 2006
Status
Revoked
Mar 8, 2024
Grant Date
Dec 13, 2017
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (3)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

JANSSEN SCIENCES IRELAND UCSep 13, 2018CARPMAELS & RANSFORDADMISSIBLE
REGENERON PHARMACEUTICALSSep 12, 2018J A KEMPADMISSIBLE
SANOFISep 11, 2018CARPMAELS & RANSFORDADMISSIBLE

Patent Citations (38) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS2002106730
DESCRIPTIONUS2002107363
DESCRIPTIONUS2002110836
DESCRIPTIONUS2002160000
DESCRIPTIONUS2002164600
DESCRIPTIONUS2003039653
DESCRIPTIONUS2003044768
DESCRIPTIONUS2003064380
DESCRIPTIONUS2003166531
DESCRIPTIONUS2003232323
DESCRIPTIONUS2004137577
DESCRIPTIONUS3625214
DESCRIPTIONUS4230767
DESCRIPTIONUS4233402
DESCRIPTIONUS4275149
DESCRIPTIONUS4376110
DESCRIPTIONUS4659678
DESCRIPTIONUS4727022
DESCRIPTIONUS4789734
DESCRIPTIONUS4925673
DESCRIPTIONUS5698520
DESCRIPTIONUS5954687
DESCRIPTIONUS6368832
DESCRIPTIONUS6579854
DESCRIPTIONUS6808710
DESCRIPTIONWO8907136
OPPOSITIONUS2007122378
OPPOSITIONWO0114557
OPPOSITIONWO0200730
OPPOSITIONWO02079499
OPPOSITIONWO02086083
OPPOSITIONWO2004004771
OPPOSITIONWO2007005874
OTHERWO2004004771
SEARCHEP1537878
SEARCHWO0200730
SEARCHWO2004004771
SEARCHWO2004056875

Non-Patent Literature (NPL) Citations (32) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- AHMED ET AL., J. VIROL., (1984), vol. 51, pages 34 - 41-
DESCRIPTION- BERZOFSKY ET AL., J. CLIN. INVEST., (2004), vol. 114, pages 456 - 462-
DESCRIPTION- "Clinical Interpretation Of Laboratory Procedures", SHULTZ, Fundamentals of Clinical Chemistry, W.B. SAUNDERS COMPANY, (1996), pages 192 - 199-
DESCRIPTION- DONG ET AL., NATURE, (1999), vol. 5, pages 1365 - 1369-
DESCRIPTION- GREGORIADIS, Drug Carriers in Biology and Medicine, ACADEMIC PRESS, (1979), pages 287 - 341-
DESCRIPTION- ISHIDA ET AL., EMBO J., (1992), vol. 11, pages 3887 - 3895-
DESCRIPTION- JOLIOT ET AL., PROC NATL ACAD SCI USA, (1991), vol. 88, pages 1864 - 1868-
DESCRIPTION- KAECH ET AL., CELL, (2002), vol. 111, pages 837 - 51-
DESCRIPTION- KANG ET AL., SCIENCE, (1992), vol. 257, page 1134-
DESCRIPTION- KOTIN ET AL., PROC. NATL. ACAD. SCI. USA, (1990), vol. 87, pages 2211 - 2215-
DESCRIPTION- LU ET AL., Abstracts of the Meeting on Gene Therapy, COLD SPRING HARBOR LABORATORY, page 66-
DESCRIPTION- O'MARCAIGH AS, JACOBSON RM, "Estimating The Predictive Value Of A Diagnostic Test, How To Prevent Misleading Or Confusing Results", CLIN. PED., (1993), vol. 32, no. 8, pages 485 - 491-
DESCRIPTION- ROSENBERG ET AL., N. ENG. J. MED., (1990), vol. 323, no. 9, pages 570 - 578-
DESCRIPTION- SHINOHARA ET AL., GENOMICS, (1994), vol. 23, pages 704 - 706-
DESCRIPTION- WHERRY ET AL., J. VIROL., (2003), vol. 77, pages 4911 - 27-
DESCRIPTION- ZWEIG ET AL., "ROC Curve Analysis: An Example Showing The Relationships Among Serum Lipid And Apolipoprotein Concentrations In Identifying Patients With Coronory Artery Disease", CLIN. CHEM., (1992), vol. 38, no. 8, pages 1425 - 1428-
OPPOSITION- CARUNTU et al., "CccDNA Persistence during Natural Evolution of Chronic VHB Infection", Romanian J. Gastroenterology, (20051200), vol. 14, no. 4, pages 373 - 377, XP055519560-
OPPOSITION- ISOGAWA et al., "Oscillating CDS+ T Cell Effector Functions after Antigen Recognition in the Liver", Immunity, (20050000), vol. 23, no. 1, pages 53 - 63, XP055519557-
OPPOSITION- KIRCHBERGER et al., "Human Rhinoviruses Inhibit the Accessory Function of Dendritic Cells by Inducing Sialoadhesin and B7-Hl Expression1", J. Immunol., (20050000), vol. 175, no. 2, pages 1145 - 1152, XP055519558-
OPPOSITION- OKAZAKI et al., "The PD-1-PD-L pathway in immunological tolerance", Trends in Immunology, (20060000), vol. 27, no. 4, pages 195 - 201, XP005365361
OPPOSITION- BARBER et al., "Restoring function in exhausted CD8 T cells during chronic viral infection", Nature, (20060000), vol. 439, no. 7077, pages 682 - 687, XP002419629
OPPOSITION- NAKAMOTO et al., "Functional Restoration of HCV-Specific CD8 T Cells by PD-1 Blockade Is Defined by PD-1 Expression and Compartmentalization", Gastroenterology, (20080000), vol. 134, no. 7, pages 1927 - 1937, XP022694434
OPPOSITION- IWAI et al., "PD-1 Inhibits Antiviral Immunity at the Effector Phase in the Liver", J. Exp. Med., (20030000), vol. 198, no. 1, pages 39 - 50, XP055011230
OPPOSITION- TRABATTONI et al., "B7-H1 is up-regulated in HIV infection and is a novel surrogate marker of disease progression", Blood, (20030000), vol. 101, no. 7, pages 2514 - 20, XP002419628
OPPOSITION- JEON et al., "PD-L1/B-7-H1 regulates the survival but not the function of CD8+ T cells in HSV-1 latently infected trigeminal ganglia", J. Immunol., (20130000), vol. 190, no. 12, pages 6277 - 6286, XP055519561
SEARCH- HE LANXIANG ET AL, "Blockade of B7-H1 with sPD-1 improves immunity against murine hepatocarcinoma.", ANTICANCER RESEARCH 2005 SEP-OCT, (200509), vol. 25, no. 5, ISSN 0250-7005, pages 3309 - 3313, XP009078741 [AP] 1 * abstract *-
SEARCH- HIRANO FUMIYA ET AL, "Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity.", CANCER RESEARCH 1 FEB 2005, (20050201), vol. 65, no. 3, ISSN 0008-5472, pages 1089 - 1096, XP002419626 [X] 1 * page 1091, column R *-
SEARCH- BLANK CHRISTIAN ET AL, "Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy.", CANCER IMMUNOLOGY, IMMUNOTHERAPY : CII APR 2005, (200504), vol. 54, no. 4, ISSN 0340-7004, pages 307 - 314, XP002419627 [A] 1 * figure 2 *
SEARCH- BARBER DANIEL L ET AL, "Restoring function in exhausted CD8 T cells during chronic viral infection.", NATURE 9 FEB 2006, (20060209), vol. 439, no. 7077, ISSN 1476-4687, pages 682 - 687, XP002419629 [AP] 1-17 * the whole document *
SEARCH- IWAI YOSHIKO ET AL, "Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, (20020917), vol. 99, no. 19, ISSN 0027-8424, pages 12293 - 12297, XP002398159 [A] 1 * page 12295 *
SEARCH- OHIGASHI YUICHIRO ET AL, "Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH 15 APR 2005, (20050415), vol. 11, no. 8, ISSN 1078-0432, pages 2947 - 2953, XP002419631 [A] 1 * the whole document *
SEARCH- TRABATTONI DARIA ET AL, "B7-H1 is up-regulated in HIV infection and is a novel surrogate marker of disease progression.", BLOOD 1 APR 2003, (20030401), vol. 101, no. 7, ISSN 0006-4971, pages 2514 - 2520, XP002419628 [Y] 2,3 * page 2516 *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents